Cingulate, Inc. (NASDAQ:CING) reported 2024 results on March 26 th, 2025. No revenues were recorded and operating expense of $15.6 million was recognized. Over the last several months, Cingulate ...

KANSAS CITY, Kan., March 26, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery ...